1h Free Analyst Time
The alpha glucosidase inhibitors market is forecasted to grow by USD 476.8 million during 2023-2028, accelerating at a CAGR of 2.12% during the forecast period. The report on the alpha glucosidase inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increase in awareness of diabetes and growing initiatives, growing awareness about benefits of alpha glucosidase inhibitors, and increasing prevalence of dumping syndrome globally.
The alpha glucosidase inhibitors market is segmented as below:
By Disease Type
- Type 2 diabetes
- Dumping syndrome
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the alpha glucosidase inhibitors market covers the following areas:
- Alpha glucosidase inhibitors market sizing
- Alpha glucosidase inhibitors market forecast
- Alpha glucosidase inhibitors market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Disease Type
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global alpha glucosidase inhibitors market: Anderson Hay and Grain Co. Inc., AstraZeneca Plc, Bayer AG, BioVision Inc., Boehringer Ingelheim International GmbH, Border Valley Trading, Bristol Myers Squibb Co., Eli Lilly and Co., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Merck KGaA, Novartis AG, Novo Nordisk AS, Pfizer Inc., Sanofi SA, Straight Healthcare, Sun Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Co. Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is growing geriatric population."
According to the report, one of the major drivers for this market is the increase in awareness of diabetes and growing initiatives.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Anderson Hay and Grain Co. Inc.
- AstraZeneca Plc
- Bayer AG
- BioVision Inc.
- Boehringer Ingelheim International GmbH
- Border Valley Trading
- Bristol Myers Squibb Co.
- Eli Lilly and Co.
- GlaxoSmithKline Plc
- Glenmark Pharmaceuticals Ltd.
- Merck KGaA
- Novartis AG
- Novo Nordisk AS
- Pfizer Inc.
- Sanofi SA
- Straight Healthcare
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Co. Ltd.
